Metabolic associated fatty liver disease
Conditions
Interventions
Gold Standard:NAFLD Activity Score and Fibrosis Staging of Liver Biopsy Specimens
Index test:lipotoxic metabolites in exosome (lysophospholipids?ceramides)
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Population meeting the diagnostic criteria specified in the Guidelines for the Prevention and Treatment of Metabolic Dysfunction-Associated (Non-Alcoholic) Fatty Liver Disease (2024 Edition), with fatty liver disease of other etiologies excluded, and possessing complete clinical baseline data, laboratory examination data and imaging examination data. 2. Population who voluntarily undergo liver biopsy and have qualified pathological specimens; 3. Inclusion Criteria for MAFLD Subgroups : (1) Patients must meet the general inclusion criteria, and be diagnosed with simple fatty liver disease definitively by liver biopsy pathology. The pathological findings show no hepatocellular ballooning, with mild or no lobular inflammation, and a NAS of less than 3; (2) Patients with liver fibrosis staged as Metavir F0 or Metavir F1; 4. Inclusion Criteria for MASH Subgroups : 1.Patients must meet the general inclusion criteria, and be diagnosed with MASH definitively by liver biopsy pathology. Core pathological features must be satisfied: hepatocellular steatosis (>=5%) + hepatocellular ballooning + lobular inflammation. A definitive MASH diagnosis requires a NAS >=5; alternatively, MASH can be diagnosed with a NAS score of 3–4 combined with clinical high-risk factors. (2) Patients with liver fibrosis staged as Metavir F1, F2, or F3.
Exclusion criteria
Exclusion criteria: 1. Individuals with incomplete clinicopathological data; 2. Individuals with viral hepatitis, autoimmune hepatitis, or other known chronic liver diseases; 3. Individuals taking potential hepatotoxic drugs; 4. Individuals with heavy alcohol consumption (>=140 grams/week for males or >=70 grams/week for females). 5. Patients with liver fibrosis staged as Metavir F4.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic Exosomal Lipid Metabolite Components;NASH Activity Score;Fibrosis Staging;sensitivity;specificity;Positive Predictive Value;Negative Predictive Value; | — |
Countries
China
Contacts
Public ContactXiuqing Huang
Beijing Hospital
Outcome results
None listed